Author Of 1 Presentation
HFNC IN BRONCHIOLITIS: DOES IT HAVE AN IMPACT ON PICU ADMISSION OR THE LENGTH OF STAY?
Abstract
Background
In recent years, ventilatory support in severe bronchiolitis has changed, with increased use of non-invasive ventilation (NIV) and the implementation of high-flow nasal cannula oxygen therapy (HFNC).
Objectives
Analyse the impact of HFNC on patients with bronchiolitis: admission to PICU, length of stay (LOS) in the PICU, LOS in the hospital, describing changes observed between the periods 2010-2011 and 2016-2018.
Methods
Retrospective, observational, descriptive and comparative study of patients younger than one year that were admitted to the PICU with bronchiolitis. Demographic and clinical data collected include the ventilatory support received: HFNC, NIV or conventional mechanical ventilation (CMV), and the use of HFNC after CMV or NIV. LOS in both the PICU and the hospital was recorded. Statistical significance was set at p <0.05.
Results
248 patients were included; 53 from 2010/2011 and 195 from 2016/2018. No differences were found between clinical variables at admission, nor in the LOS in PICU. The use of HFNC before PICU admission was significantly greater in 2016/2018. There was a 3% reduction in PICU admissions between the two periods, and the need for CMV decreased around 20% in the second period. Hospital’s LOS was significantly shorter for patients who received pre-admission HFNC 17.8 versus 11 days (p= 0.0005). HFNC for weaning did not reduce the PICU’s LOS 7 versus 7.5 days (p= 0.7).
Conclusion
The use of HFNC does not significantly reduce PICU admission, nor LOS in the PICU. However, a significant reduction in hospital LOS is observed for patients receiving pre-admission HFNC.
Presenter of 1 Presentation
HFNC IN BRONCHIOLITIS: DOES IT HAVE AN IMPACT ON PICU ADMISSION OR THE LENGTH OF STAY?
Abstract
Background
In recent years, ventilatory support in severe bronchiolitis has changed, with increased use of non-invasive ventilation (NIV) and the implementation of high-flow nasal cannula oxygen therapy (HFNC).
Objectives
Analyse the impact of HFNC on patients with bronchiolitis: admission to PICU, length of stay (LOS) in the PICU, LOS in the hospital, describing changes observed between the periods 2010-2011 and 2016-2018.
Methods
Retrospective, observational, descriptive and comparative study of patients younger than one year that were admitted to the PICU with bronchiolitis. Demographic and clinical data collected include the ventilatory support received: HFNC, NIV or conventional mechanical ventilation (CMV), and the use of HFNC after CMV or NIV. LOS in both the PICU and the hospital was recorded. Statistical significance was set at p <0.05.
Results
248 patients were included; 53 from 2010/2011 and 195 from 2016/2018. No differences were found between clinical variables at admission, nor in the LOS in PICU. The use of HFNC before PICU admission was significantly greater in 2016/2018. There was a 3% reduction in PICU admissions between the two periods, and the need for CMV decreased around 20% in the second period. Hospital’s LOS was significantly shorter for patients who received pre-admission HFNC 17.8 versus 11 days (p= 0.0005). HFNC for weaning did not reduce the PICU’s LOS 7 versus 7.5 days (p= 0.7).
Conclusion
The use of HFNC does not significantly reduce PICU admission, nor LOS in the PICU. However, a significant reduction in hospital LOS is observed for patients receiving pre-admission HFNC.